SCHEMBL3717132

SCHEMBL3717132

FC(F)(F)Oc1ccc(Cl)c(Br)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR3 P46089 5/20 0.44
▸ GAA P10253 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ FFAR4 Q5NUL3 6/20 0.40
▸ SCN5A Q14524 3/20 0.40
▸ CYP2C9 P11712 2/20 0.40
▸ FFAR1 O14842 1/20 0.40
▸ AKR1C2 P52895 1/20 0.39
▸ AKR1C1 Q04828 1/20 0.39
▸ KIF11 P52732 1/20 0.39
▸ TRPV1 Q8NER1 1/20 0.38
▸ CES1 P23141 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ EPAS1 Q99814 1/20 0.37
▸ CYP3A4 P08684 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30448828 1.00 GPR3 (0.44) GPR3GAAALDH1A1POLBTHRB
SCHEMBL29758243 0.84 GPR3 (0.44) GPR3GAAALDH1A1POLBTHRB
SCHEMBL3750038 0.84 GPR3 (0.44) GPR3GAAALDH1A1POLBTHRB
SCHEMBL24441001 0.82 EPAS1 (0.34) GAAALDH1A1POLBTHRBTRPV1
SCHEMBL8065084 0.81 GPR3 (0.48) GPR3FFAR4SCN5ACYP2C9FFAR1
SCHEMBL29894167 0.81 GPR3 (0.48) GPR3FFAR4SCN5ACYP2C9FFAR1
SCHEMBL30018924 0.78 GPR3 (0.46) GPR3GAAALDH1A1POLBTHRB
SCHEMBL15718212 0.78 GPR3 (0.46) GPR3GAAALDH1A1POLBTHRB
SCHEMBL11065683 0.78 FFAR4 (0.48) GPR3FFAR4SCN5ACYP2C9FFAR1
SCHEMBL19643066 0.76 ALDH1A1 (0.34) GPR3GAAALDH1A1POLBTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479844-B2 Ion channel modulators PRAXIS PRECISION MEDICINES, INC. (US) 2025-11-25 — — US disclosed
US-20250163068-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2025-05-22 — — US disclosed
US-20250145629-A1 ION CHANNEL MODULATORS PRAXIS PRECISION MEDICINES, INC. 2025-05-08 — — US disclosed
US-20250034122-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2025-01-30 — — US disclosed
US-12145939-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators PRAXIS PRECISION MEDICINES, INC. (US) 2024-11-19 — — US disclosed
EP-4441044-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2024-10-09 — — EP disclosed
EP-4397308-A2 COMPOUNDS AND THEIR METHODS OFUSE Praxis Precision Medicines, Inc. (US) 2024-07-10 — — EP disclosed
CN-118302422-A Substituted N-cyanopyrrolidines having activity as USP30 inhibitors 特殊治疗有限公司 2024-07-05 — — CN disclosed
EP-3548033-B1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2024-04-10 — — EP disclosed
US-11918571-B2 Compounds and their methods of use PRAXIS PRECISION MEDICINES, INC. (US) 2024-03-05 — — US disclosed
EP-2398796-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE Merck Canada Inc. (CA) 2011-12-28 — — EP disclosed
US-20110301143-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK CANADA INC. (CA) 2011-12-08 — — US disclosed
WO-2010094126-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2010-08-26 — — WO disclosed
EP-1551836-A1 AZABICYCLIC AMINE DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2005-07-13 — — EP disclosed
WO-2004031190-A1 AZABICYCLIC AMINE DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2004-04-15 — — WO disclosed
US-6555552-B2 Psychological disorders; analgesics; antiinflammatory agents MERCK SHARP & DOHME LTD. (GB) 2003-04-29 — — US disclosed
US-20020147212-A1 Azabicyclic amine derivatives and their use as therapeutic agents MERCK SHARP & DOHME LTD. (GB) 2002-10-10 — — US disclosed
EP-0109606-B1 PROCESS FOR THE FORMYLATION OF ARYL HALIDES BAYER AG (DE) 1986-01-22 — — EP disclosed
US-4536344-A USING A PHOSPINE OR PHOSPHITE BAYER AKTIENGESELLSCHAFT (DE) 1985-08-20 — — US disclosed
EP-0109606-A1 Process for the formylation of aryl halides BAYER AG (DE) 1984-05-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11918571-B2 Compounds and their methods of use SCN1A, SCN3A, SCN2A GPR3 1391/4885GAA 935/4885ALDH1A1 1162/4885
US-20020147212-A1 Azabicyclic amine derivatives and their use as therapeutic agents CXCR1, CXCR6, CCR6 GPR3 268/4885GAA 1432/4885ALDH1A1 1514/4885
US-20250034122-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS USP30, USP47, USP1 GPR3 3832/4885GAA 3398/4885ALDH1A1 707/4885
US-12145939-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators SCN1A, SCN2A, SCN5A GPR3 462/4885GAA 3554/4885ALDH1A1 1576/4885
US-20250145629-A1 ION CHANNEL MODULATORS SCN1A, SCN3A, SCN2A GPR3 722/4885GAA 2007/4885ALDH1A1 1953/4885
US-20250163068-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B GPR3 1830/4885GAA 832/4885ALDH1A1 916/4885
US-12479844-B2 Ion channel modulators SCN1A, SCN3A, SCN2A GPR3 722/4885GAA 2007/4885ALDH1A1 1953/4885
US-20110301143-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE SCD, SCD5, COASY GPR3 1302/4885GAA 1743/4885ALDH1A1 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback